109 related articles for article (PubMed ID: 2117787)
1. Praziquantel in the treatment of hepatosplenic schistosomiasis: biochemical disease markers indicate deceleration of fibrogenesis and diminution of portal flow obstruction.
Zwingenberger K; Richter J; Vergetti JG; Feldmeier H
Trans R Soc Trop Med Hyg; 1990; 84(2):252-6. PubMed ID: 2117787
[TBL] [Abstract][Full Text] [Related]
2. Liver involvement in human schistosomiasis mansoni. Regression of immunological and biochemical disease markers after specific treatment.
Zwingenberger K; Harms G; Feldmeier H; Müller O; Steiner A; Bienzle U
Acta Trop; 1988 Sep; 45(3):263-75. PubMed ID: 2903628
[TBL] [Abstract][Full Text] [Related]
3. Tumour necrosis factor in hepatosplenic schistosomiasis.
Zwingenberger K; Irschick E; Vergetti Siqueira JG; Correia Dacal AR; Feldmeier H
Scand J Immunol; 1990 Feb; 31(2):205-11. PubMed ID: 2106723
[TBL] [Abstract][Full Text] [Related]
4. Liver involvement in human schistosomiasis mansoni. Assessment by immunological and biochemical markers.
Zwingenberger K; Feldmeier H; Queiroz JA; Siqueira JG; Auto HF; Alencar JE; Bienzle U
Parasitol Res; 1988; 74(5):448-55. PubMed ID: 3137558
[TBL] [Abstract][Full Text] [Related]
5. Re-infection in human schistosomiasis mansoni: a prospective field study 18 months after praziquantel therapy.
Zwingenberger K; Harms G; Poggensee U; Steiner A; Müller O; Feldmeier H
Ann Trop Med Parasitol; 1990 Oct; 84(5):457-65. PubMed ID: 2124097
[TBL] [Abstract][Full Text] [Related]
6. Effect of oxamniquine and praziquantel on intrasplenic pressure and portal vein diameter in hepatosplenic schistosomiasis.
Massoud AM; Ghoneem M; Massoud M
J Egypt Soc Parasitol; 1986 Dec; 16(2):427-37. PubMed ID: 3782898
[No Abstract] [Full Text] [Related]
7. [Hepatosplenic schistosomiasis: case report and clinical review].
Wirth HP; Casanova C; Meyenberger C; Hammer B; Ammann R; Blum HE
Schweiz Med Wochenschr; 1993 Oct; 123(42):1991-5. PubMed ID: 8259482
[TBL] [Abstract][Full Text] [Related]
8. Serum type III procollagen peptides in patients with hepatointestinal and compensated hepatoesplenic schistosomiasis forms.
Mincis M; Braga LL; Russo EM; Novo NF; Juliano Y
Arq Gastroenterol; 1990; 27(1):24-9. PubMed ID: 1978659
[TBL] [Abstract][Full Text] [Related]
9. Reduction of morbidity in hepatosplenic schistosomiasis mansoni after treatment with praziquantel: a long term study.
Domingues AL; Coutinho AD
Rev Soc Bras Med Trop; 1990; 23(2):101-7. PubMed ID: 2129517
[TBL] [Abstract][Full Text] [Related]
10. Praziquantel in the treatment of the hepatosplenic form of Schistosomiasis mansoni.
da Silva LC; Sette H; Christo CH; Sáez-Alquezar A; Carneiro CR; Lacet CM; Ohtsuki N; Raia S
Arzneimittelforschung; 1981; 31(3a):601-3. PubMed ID: 7195256
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of hepatosplenic schistosomiasis mansoni with praziquantel].
Coutinho AD; Domingues AL; Florêncio JN; Almeida ST
Rev Inst Med Trop Sao Paulo; 1984; 26(1):38-50. PubMed ID: 6379831
[No Abstract] [Full Text] [Related]
12. Aminoterminal propeptide of type III procollagen: a marker of disease activity in schistosomal patients.
Fayol V; Hassanein HI; el-Badrawy N; Ville G; Hartmann DJ
Eur J Clin Chem Clin Biochem; 1991 Nov; 29(11):737-41. PubMed ID: 1782280
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatosplenic Schistosomiasis mansoni with praziquantel. Preliminary report on tolerance and efficacy.
Coutinho A; Domingues AL; Neves J; Almeida ST
Arzneimittelforschung; 1983; 33(5):787-91. PubMed ID: 6683560
[No Abstract] [Full Text] [Related]
14. Enzyme activities and protein concentrations in serum of patients with hepatosplenic schistosomiasis.
Abdel-Rahim IM; Kaiser C; Homeida M; Elsheikh M; Schmidt E; Ehrich JH; Doehring-Schwerdfeger E
Trop Med Parasitol; 1990 Sep; 41(3):262-4. PubMed ID: 1701559
[TBL] [Abstract][Full Text] [Related]
15. Assessment of portal hemodynamics by Doppler ultrasound and of liver morphology in the hepatosplenic and hepatointestinal forms of schistosomiasis mansoni.
Vezozzo DC; Farias AQ; Cerri GG; Da Silva LC; Carrilho FJ
Dig Dis Sci; 2006 Aug; 51(8):1413-9. PubMed ID: 16868833
[TBL] [Abstract][Full Text] [Related]
16. Changes of ultrasonography and two serum biochemical indices for hepatic fibrosis in schistosomiasis japonica patients one year after praziquantel treatment.
Cai W; Chen Z; Chen F; Zhou C; Liu R; Wang J
Chin Med J (Engl); 1997 Oct; 110(10):797-800. PubMed ID: 9642313
[TBL] [Abstract][Full Text] [Related]
17. Hepatosplenic schistosomiasis: playing hide-and-seek with an elusive parasite.
Baekby M; Glerup H; Stribolt K; Tarp B
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28814579
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the cytokines IL-10 and IL-13 as mediators in the progression of Symmers fibrosis in patients with hepatosplenic schistosomiasis mansoni.
Brandt CT; Rino M; Pitta MG; Muniz JS; Silveira Dde O; Castro CM
Rev Col Bras Cir; 2010 Oct; 37(5):333-7. PubMed ID: 21180998
[TBL] [Abstract][Full Text] [Related]
19. Improvement of ultrasonographic and serologic changes in Schistosoma japonicum-infected patients after treatment with praziquantel.
Ohmae H; Tanaka M; Hayashi M; Matsuzaki Y; Kurosaki Y; Blas BL; Portillo GG; Sy OS; Irie Y; Yasuraoka K
Am J Trop Med Hyg; 1992 Jan; 46(1):99-104. PubMed ID: 1536391
[TBL] [Abstract][Full Text] [Related]
20. Hypoprothrombinemia in the compensated form of hepatosplenic schistosomiasis: further studies.
Manoukian N; Borges DR
Rev Inst Med Trop Sao Paulo; 1988; 30(4):274-80. PubMed ID: 3149416
[No Abstract] [Full Text] [Related]
[Next] [New Search]
